These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32048107)

  • 1. A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
    Yee KL; Kleijn HJ; Zajic S; Dorr MB; Wrishko RE
    J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):121-130. PubMed ID: 32048107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent
    Yee KL; Kleijn HJ; Kerbusch T; Matthews RP; Dorr MB; Garey KW; Wrishko RE
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
    Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
    Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
    Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
    Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
    Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
    BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
    Zeng Z; Zhao H; Dorr MB; Shen J; Wilcox MH; Poxton IR; Guris D; Li J; Shaw PM
    Anaerobe; 2020 Feb; 61():102137. PubMed ID: 31846705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes After Fecal Microbiota Transplantation in Combination With Bezlotoxumab for Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection.
    Allegretti JR; Axelrad J; Dalal RS; Kelly CR; Grinspan A; Fischer M
    Am J Gastroenterol; 2024 Jul; 119(7):1433-1436. PubMed ID: 38501667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
    Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
    J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.
    Kelly CP; Poxton IR; Shen J; Wilcox MH; Gerding DN; Zhao X; Laterza OF; Railkar R; Guris D; Dorr MB
    Clin Infect Dis; 2020 Jun; 71(1):81-86. PubMed ID: 31628838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
    Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
    J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
    Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
    Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
    Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
    Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
    Villafuerte Gálvez JA; Kelly CP
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breaking the Cycle of Recurrent
    Herbin SR; Crum H; Gens K
    J Pharm Pract; 2024 Dec; 37(6):1361-1373. PubMed ID: 38739837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.